MXPA03001632A - Moduladores receptores de androgeno selectivos y metodos para usar los mismos. - Google Patents
Moduladores receptores de androgeno selectivos y metodos para usar los mismos.Info
- Publication number
- MXPA03001632A MXPA03001632A MXPA03001632A MXPA03001632A MXPA03001632A MX PA03001632 A MXPA03001632 A MX PA03001632A MX PA03001632 A MXPA03001632 A MX PA03001632A MX PA03001632 A MXPA03001632 A MX PA03001632A MX PA03001632 A MXPA03001632 A MX PA03001632A
- Authority
- MX
- Mexico
- Prior art keywords
- androgen receptor
- agents
- prostate cancer
- compounds
- androgen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
Abstract
Esta invencion proporciona una nueva clase de agentes objetivo receptores de androgeno (ARTA). Los agentes definen una nueva subclase de compuestos que son modulares receptores de androgeno selectivos de tejido (SARM), que son utiles para la terapia de reemplazo de testosterona oral, contracepcion masculina, mantenimiento del deseo sexual en mujeres, tratamiento del cancer de prostata y representacion del cancer de prostata. Estos agentes tienen una actividad in vivo inesperada para una actividad anabolica y androgenica de un ligando no esteroidal para el receptor de androgeno. Estos agentes pueden ser activos solos o en combinacion con progestinas o estrogenos. La invencion proporciona ademas una nueva clase de compuestos agonistas no esteroidales. La invencion proporciona ademas composiciones que contienen los compuestos modulares de androgeno selectivos o los compuestos agonistas no esteroidales y metodos para unir un receptor de androgeno, modular la espermatogenesis, tratar y representar el cancer de prostata, y proporcionar terapia hormonal para condiciones dependientes del androgeno.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64497000A | 2000-08-24 | 2000-08-24 | |
US30008301P | 2001-06-25 | 2001-06-25 | |
PCT/US2001/026328 WO2002016310A1 (en) | 2000-08-24 | 2001-08-23 | Selective androgen receptor modulators and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03001632A true MXPA03001632A (es) | 2004-09-10 |
Family
ID=26971579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03001632A MXPA03001632A (es) | 2000-08-24 | 2001-08-23 | Moduladores receptores de androgeno selectivos y metodos para usar los mismos. |
Country Status (21)
Country | Link |
---|---|
US (1) | US6569896B2 (es) |
EP (4) | EP1705174A1 (es) |
JP (2) | JP2004518617A (es) |
KR (1) | KR20030061783A (es) |
CN (2) | CN1736371B (es) |
AT (2) | ATE344233T1 (es) |
AU (2) | AU2001285230C1 (es) |
BR (1) | BR0114801A (es) |
CA (1) | CA2420279C (es) |
CY (2) | CY1105956T1 (es) |
DE (2) | DE60124322T2 (es) |
DK (2) | DK1491524T3 (es) |
EA (2) | EA007101B1 (es) |
ES (2) | ES2321933T3 (es) |
GE (1) | GEP20053586B (es) |
HK (2) | HK1062011A1 (es) |
HR (1) | HRP20030118B1 (es) |
MX (1) | MXPA03001632A (es) |
PT (2) | PT1401801E (es) |
SI (1) | SI1401801T1 (es) |
WO (1) | WO2002016310A1 (es) |
Families Citing this family (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US7518013B2 (en) * | 2000-08-24 | 2009-04-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators |
US20050038110A1 (en) * | 2000-08-24 | 2005-02-17 | Steiner Mitchell S. | Selective androgen receptor modulators and methods of use thereof |
US6995284B2 (en) | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
US20040176470A1 (en) * | 1998-05-07 | 2004-09-09 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
AU779931B2 (en) * | 1999-12-16 | 2005-02-17 | Teva Pharmaceutical Industries Ltd. | Novel processes for making- and a new crystalline form of- leflunomide |
US20070173546A1 (en) * | 2000-08-24 | 2007-07-26 | Dalton James T | Selective androgen receptor modulators and method of use thereof |
US6838484B2 (en) | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
US7919647B2 (en) * | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US6998500B2 (en) | 2000-08-24 | 2006-02-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
US8008348B2 (en) | 2001-12-06 | 2011-08-30 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
US20040260108A1 (en) * | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
US7026484B2 (en) * | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
US20060004042A1 (en) * | 2001-08-23 | 2006-01-05 | Dalton James T | Formulations comprising selective androgen receptor modulators |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
WO2003049675A2 (en) * | 2001-12-06 | 2003-06-19 | Gtx, Inc. | Treating muscle wasting with selective androgen receptor modulators |
US8853266B2 (en) * | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
CN101732298B (zh) * | 2002-02-07 | 2012-09-19 | 田纳西大学研究基金会 | 用sarms治疗良性前列腺增生 |
US7803970B2 (en) * | 2002-02-28 | 2010-09-28 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
MXPA04009460A (es) * | 2002-02-28 | 2006-04-27 | Univ Tennessee Res Foundation | Moduladores receptores de androgeno selectivo multi-sustituidos y metodos de uso de los mismos. |
JP5113979B2 (ja) * | 2002-02-28 | 2013-01-09 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法 |
US7344700B2 (en) | 2002-02-28 | 2008-03-18 | University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
US7772433B2 (en) * | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
EP2266577B8 (en) * | 2002-02-28 | 2015-01-21 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
EP1487780A4 (en) * | 2002-02-28 | 2005-11-16 | Univ Tennessee Res Foundation | HALOGENACETAMIDE AND AZIDSUBSTITUTED COMPOUNDS AND METHOD FOR THEIR USE |
AU2003214971A1 (en) * | 2002-02-28 | 2003-09-16 | University Of Tennessee Research Foundation | Irreversible selective androgen receptor modulators and methods of use thereof |
US7741371B2 (en) * | 2002-06-17 | 2010-06-22 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
WO2003106401A1 (en) * | 2002-06-17 | 2003-12-24 | University Of Tennessee Research Foundation | N-bridged selective androgen receptor modulators and methods of use thereof |
EP1562594A4 (en) * | 2002-10-15 | 2008-12-17 | Univ Tennessee Res Foundation | SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH METHYLENE BRIDGES AND METHOD OF USE THEREOF |
CN1726193A (zh) * | 2002-10-15 | 2006-01-25 | 田纳西大学研究基金会 | 杂环选择性雄激素受体调节剂及其使用方法 |
US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
EP1558233A2 (en) * | 2002-10-16 | 2005-08-03 | GTX, Inc. | Treating androgen decline in aging male (adam)-associated conditions with sarms |
US20040087810A1 (en) * | 2002-10-23 | 2004-05-06 | Dalton James T. | Irreversible selective androgen receptor modulators and methods of use thereof |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
CA2513242C (en) * | 2003-01-13 | 2013-07-09 | Gtx Inc. | Large-scale synthesis of selective androgen receptor modulators |
JP2006516286A (ja) * | 2003-01-22 | 2006-06-29 | ジーティーエックス・インコーポレイテッド | Sarmによる女性のアンドロゲン減少に関連する病気の治療 |
US20040167103A1 (en) * | 2003-02-24 | 2004-08-26 | Dalton James T. | Haloacetamide and azide substituted compounds and methods of use thereof |
ES2291906T3 (es) * | 2003-06-13 | 2008-03-01 | Janssen Pharmaceutica N.V. | Derivados de tiazolina como moduladores selectivos del receptor del androgeno (sarms). |
FI20030958A0 (fi) * | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
CN100462353C (zh) * | 2003-06-27 | 2009-02-18 | 奥赖恩公司 | 用作雄激素受体调节剂的丙酰胺衍生物 |
DE602004026583D1 (de) * | 2003-06-27 | 2010-05-27 | Orion Corp | Als androgenrezeptormodulatoren geeignete propionamidderivate |
MXPA06001751A (es) | 2003-08-22 | 2006-05-12 | Ligand Pharm Inc | Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno. |
EP2476415A3 (en) * | 2003-10-14 | 2012-08-29 | University of Tennessee Research Foundation | Treating bone-related disorders with selective androgen receptor modulators |
GB0324551D0 (en) * | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
US7202234B2 (en) * | 2003-10-24 | 2007-04-10 | Eisai Co., Ltd. | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions |
JP2007512359A (ja) | 2003-11-19 | 2007-05-17 | メタバシス・セラピューティクス・インコーポレイテッド | 新規なリン含有甲状腺ホルモン様物質 |
JP2007513998A (ja) * | 2003-12-16 | 2007-05-31 | ジーティーエックス・インコーポレイテッド | 選択的アンドロゲン受容体調節剤のプロドラッグ及びその使用方法 |
ES2523017T3 (es) * | 2004-03-03 | 2014-11-20 | Glaxosmithkline Llc | Derivados de anilina como moduladores selectivos de los receptores de andrógenos |
WO2005090282A1 (en) * | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
EP1771413B1 (en) * | 2004-05-03 | 2011-09-21 | Janssen Pharmaceutica NV | Benzofuran derivatives as selective androgen receptor modulators (sarms) |
JP2007537236A (ja) * | 2004-05-11 | 2007-12-20 | ファイザー・プロダクツ・インク | 筋骨格の脆弱性を治療するためのベンゾニトリル誘導体 |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
EA011306B8 (ru) * | 2004-06-07 | 2012-10-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Избирательные модуляторы андрогеновых рецепторов и способы их применения |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
CN102976973B (zh) * | 2004-06-07 | 2015-10-21 | 田纳西大学研究基金会 | 选择性雄激素受体调节剂及其使用方法 |
MXPA06015169A (es) * | 2004-07-08 | 2007-08-21 | Warner Lambert Co | Moduladores de androgenos. |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
EP1836202B1 (en) | 2005-01-10 | 2016-12-21 | Acadia Pharmaceuticals Inc. | Aminophenyl derivatives as selective androgen receptor modulators |
US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
AU2006259474B2 (en) | 2005-06-17 | 2011-10-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
PT2425715E (pt) * | 2005-08-31 | 2014-04-14 | Univ Tennessee Res Foundation | Tratamento dos sintomas da doença renal com moduladores seletivos de recetores de androgenios |
JP5449775B2 (ja) | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
WO2007050554A2 (en) * | 2005-10-25 | 2007-05-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying compounds that modulate phb domain protein activity and compositions thereof |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US9267937B2 (en) * | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
CN101573141B (zh) | 2006-05-15 | 2016-05-04 | 麻省理工学院 | 用于功能性颗粒的聚合物 |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
CN101528214B (zh) | 2006-08-24 | 2013-06-05 | 田纳西大学研究基金会 | 取代的n-酰基苯胺及其使用方法 |
EA019849B1 (ru) * | 2006-08-28 | 2014-06-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Способ лечения, подавления, ингибирования или уменьшения инцидентов симптомов, ассоциированных с почечным заболеванием: гипогонадизма и непроизвольной потери веса |
EP2094643B1 (en) | 2006-12-01 | 2012-02-29 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
WO2008098165A2 (en) * | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
US20090074828A1 (en) | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
CN101284795B (zh) * | 2007-04-09 | 2012-04-25 | 中国科学院上海药物研究所 | 一类非甾体雄激素受体调节剂及其医学用途 |
AU2008298901C1 (en) * | 2007-09-11 | 2013-10-03 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
ES2647538T3 (es) | 2007-09-28 | 2017-12-22 | Pfizer Inc. | Direccionamiento a células de cáncer usando nanopartículas |
BRPI0817664A2 (pt) | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
EP2222636B1 (en) | 2007-12-21 | 2013-04-10 | Ligand Pharmaceuticals Inc. | Selective androgen receptor modulators (sarms) and uses thereof |
MX2010009162A (es) | 2008-02-22 | 2010-12-21 | Radius Health Inc | Moduladores selectivos del receptor de androgeno. |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2010002075A1 (en) * | 2008-07-02 | 2010-01-07 | Pharmacostech Co., Ltd. | Methods for preparing amide derivatives |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
CA2788907A1 (en) | 2010-02-04 | 2011-08-11 | Radius Health, Inc. | Selective androgen receptor modulators |
HUE030072T2 (en) | 2010-05-12 | 2017-04-28 | Radius Health Inc | Therapeutic prescriptions |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
US8395552B2 (en) | 2010-11-23 | 2013-03-12 | Metamagnetics, Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
RU2666530C2 (ru) * | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
WO2013152170A1 (en) | 2012-04-04 | 2013-10-10 | Catylix, Inc. | Selective androgen receptor modulators |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
KR102238970B1 (ko) | 2012-07-13 | 2021-04-09 | 지티엑스, 인코포레이티드 | 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법 |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
RU2510392C1 (ru) * | 2012-12-21 | 2014-03-27 | Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) | Сокристаллическая форма бикалутамида |
US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
RS64115B1 (sr) | 2014-03-28 | 2023-04-28 | Univ Duke | Lečenje kancera dojke upotrebom selektivnih modulatora receptora estrogena |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
BR112017007916A2 (pt) * | 2014-10-16 | 2018-01-23 | Gtx Inc | compostos sarms para tratamento de distúrbios urológicos |
CN113633644A (zh) | 2014-10-22 | 2021-11-12 | 哈瓦赫治疗有限公司 | 降低乳房摄影乳腺密度和/或乳腺癌风险的方法 |
WO2016079521A1 (en) | 2014-11-20 | 2016-05-26 | University College Cardiff Consultants Limited | Androgen receptor modulators and their use as anti-cancer agents |
WO2016079522A1 (en) | 2014-11-20 | 2016-05-26 | University College Cardiff Consultants Limited | Androgen receptor modulators and their use as anti-cancer agents |
US9834507B2 (en) | 2015-04-21 | 2017-12-05 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
KR20170140291A (ko) | 2015-04-21 | 2017-12-20 | 지티엑스, 인코포레이티드 | 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법 |
RU2724103C2 (ru) | 2015-04-21 | 2020-06-22 | Джи Ти Икс, ИНК. | Селективные лиганды-разрушители андрогенных рецептов (sard) и способы их применения |
US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
US10035763B2 (en) | 2015-04-21 | 2018-07-31 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10017471B2 (en) | 2015-04-21 | 2018-07-10 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
CN108472302A (zh) | 2015-10-22 | 2018-08-31 | 哈瓦赫治疗有限公司 | 降低乳房摄影乳腺密度和/或乳腺癌风险的方法 |
US11230523B2 (en) | 2016-06-10 | 2022-01-25 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
KR20220035276A (ko) | 2016-06-22 | 2022-03-21 | 일립시스 파마 리미티드 | Ar+ 유방암 치료 방법 |
CA3047411A1 (en) | 2017-01-05 | 2018-07-12 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
WO2019217780A1 (en) | 2018-05-11 | 2019-11-14 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
CA3142193A1 (en) | 2019-06-03 | 2020-12-10 | Havah Therapeutics Pty Ltd | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use |
EP4225374A1 (en) | 2020-10-08 | 2023-08-16 | TargImmune Therapeutics AG | Immunotherapy for the treatment of cancer |
EP4001293A1 (de) * | 2020-11-23 | 2022-05-25 | Justus-Liebig-Universität Gießen | Tetrapeptid und dessen verwendung |
CN116801872A (zh) * | 2021-02-10 | 2023-09-22 | 上海奕拓医药科技有限责任公司 | 调节雄激素受体凝聚物的方法 |
WO2023079142A2 (en) | 2021-11-05 | 2023-05-11 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2024100046A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2024100044A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol |
WO2024100040A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3875229A (en) | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
US4139638A (en) | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
DE2862100D1 (en) | 1977-10-12 | 1983-01-05 | Ici Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
US4191775A (en) | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
NZ197008A (en) | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
JPS57171904A (en) | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
ATE28864T1 (de) * | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
GB8617653D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
GB8617652D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
WO1995019770A1 (en) | 1994-01-21 | 1995-07-27 | Sepracor, Inc. | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
US5609849A (en) | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US6071957A (en) | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
AU7604798A (en) | 1997-05-30 | 1998-12-30 | University Of Tennessee Research Corporation, The | Non-steroidal agonist compounds and their use in male hormone therapy |
WO1998055153A1 (en) | 1997-06-04 | 1998-12-10 | The University Of Tennessee Research Corporation | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
-
2001
- 2001-08-23 EP EP06014580A patent/EP1705174A1/en not_active Withdrawn
- 2001-08-23 CN CN2005100674946A patent/CN1736371B/zh not_active Expired - Fee Related
- 2001-08-23 AU AU2001285230A patent/AU2001285230C1/en not_active Ceased
- 2001-08-23 AT AT01964368T patent/ATE344233T1/de active
- 2001-08-23 PT PT01964368T patent/PT1401801E/pt unknown
- 2001-08-23 DE DE60124322T patent/DE60124322T2/de not_active Expired - Lifetime
- 2001-08-23 BR BR0114801-0A patent/BR0114801A/pt not_active IP Right Cessation
- 2001-08-23 KR KR10-2003-7002652A patent/KR20030061783A/ko not_active Application Discontinuation
- 2001-08-23 SI SI200130685T patent/SI1401801T1/sl unknown
- 2001-08-23 CA CA2420279A patent/CA2420279C/en not_active Expired - Lifetime
- 2001-08-23 AU AU8523001A patent/AU8523001A/xx active Pending
- 2001-08-23 MX MXPA03001632A patent/MXPA03001632A/es active IP Right Grant
- 2001-08-23 ES ES04019299T patent/ES2321933T3/es not_active Expired - Lifetime
- 2001-08-23 US US09/935,045 patent/US6569896B2/en not_active Expired - Fee Related
- 2001-08-23 GE GE5108A patent/GEP20053586B/en unknown
- 2001-08-23 DE DE60137728T patent/DE60137728D1/de not_active Expired - Lifetime
- 2001-08-23 EP EP01964368A patent/EP1401801B1/en not_active Expired - Lifetime
- 2001-08-23 DK DK04019299T patent/DK1491524T3/da active
- 2001-08-23 EA EA200300283A patent/EA007101B1/ru not_active IP Right Cessation
- 2001-08-23 ES ES01964368T patent/ES2275717T3/es not_active Expired - Lifetime
- 2001-08-23 WO PCT/US2001/026328 patent/WO2002016310A1/en active Application Filing
- 2001-08-23 AT AT04019299T patent/ATE423092T1/de active
- 2001-08-23 CN CNB018178898A patent/CN1230418C/zh not_active Expired - Fee Related
- 2001-08-23 DK DK01964368T patent/DK1401801T3/da active
- 2001-08-23 EA EA200501269A patent/EA014224B1/ru not_active IP Right Cessation
- 2001-08-23 JP JP2002521186A patent/JP2004518617A/ja active Pending
- 2001-08-23 PT PT04019299T patent/PT1491524E/pt unknown
- 2001-08-23 EP EP04019299A patent/EP1491524B1/en not_active Expired - Lifetime
- 2001-08-23 EP EP10182881A patent/EP2284149A1/en not_active Withdrawn
-
2003
- 2003-02-19 HR HR20030118A patent/HRP20030118B1/xx not_active IP Right Cessation
-
2004
- 2004-07-08 HK HK04104977A patent/HK1062011A1/xx not_active IP Right Cessation
-
2005
- 2005-05-12 HK HK05103982.9A patent/HK1072243A1/xx not_active IP Right Cessation
-
2006
- 2006-05-29 JP JP2006147596A patent/JP2006306880A/ja active Pending
-
2007
- 2007-01-26 CY CY20071100104T patent/CY1105956T1/el unknown
-
2009
- 2009-05-08 CY CY20091100497T patent/CY1110459T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03001632A (es) | Moduladores receptores de androgeno selectivos y metodos para usar los mismos. | |
WO2004035736A3 (en) | Halogenated selective androgen receptor modulators and methods of use thereof | |
MXPA04008068A (es) | Metodo para administrar moleculas de glp-1. | |
TW200407280A (en) | N-bridged selective androgen receptor modulators and methods of use thereof | |
WO2004035738A3 (en) | Methylene-bridged selective androgen receptor modulators and methods of use thereof | |
WO2004035737A3 (en) | Heterocyclic selective androgen receptor modulators and methods of use thereof | |
EP1487458A4 (en) | MULTIPLE SUBSTITUTED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHOD OF USE THEREOF | |
WO2003074449A3 (en) | Multi-substitued selective androgen receptor modulators and methods of use thereof | |
MX2009000714A (es) | Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. | |
TW200613252A (en) | Metabolites of selective androgen receptor modulators and methods of use thereof | |
AU7315301A (en) | Compounds and compositions for delivering active agents | |
PL347671A1 (en) | Compounds and compositions for delivering active agents | |
GEP20063984B (en) | Use of selective androgen receptor modulators for treating muscle wasting | |
GT200000053A (es) | Moduladores del receptor glucocorticoide. | |
SG148031A1 (en) | Use of cci-779 as an antineoplastic agent | |
WO2005000795A3 (en) | Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators | |
WO2003074473A3 (en) | Irreversible selective androgen receptor modulators and methods of use thereof | |
GB2364641A (en) | Stabilized oral pharmaceutical composition containing iodide and iodate and method | |
MXPA06000119A (es) | Profarmacos de moduladores receptores de androgenos selectivos y metodos de uso de los mismos. | |
HUP0105201A3 (en) | The treatment of andropause using pharmaceutical compositions containing estrogen agonists/antagonists and testosterone | |
HUP0202666A3 (en) | Drug delivery device, especially for the delivery of androgens | |
MXPA05010871A (es) | Metodos para administrar estrogenos y progestinas. | |
MXPA04005942A (es) | Composiciones y metodos de sintaxina 3. | |
MY140723A (en) | Method of treatment | |
DE69912477D1 (de) | Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |